Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock
NASDAQ · KYTX
6.86
Fundamentals
Market cap
$421.15M
Price / Earnings ratio
-2.8x
Price / Sales ratio
N/A
Price / Book ratio
2.6x
Return on assets
-65.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
NeutralKYTXSeptember 24, 2026
StocktwitsNeutral
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
KYTX

24/7 Wall Street
Kyverna Therapeutics Sinks 13%: Here's Why
NeutralKYTXJuly 10, 2026
24/7 Wall StreetNeutral
Kyverna Therapeutics Sinks 13%: Here's Why
KYTX

The Motley Fool
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
NeutralKYTXJune 8, 2026
The Motley FoolNeutral
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
KYTX

Stocktwits
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
NeutralKYTXApril 22, 2026
StocktwitsNeutral
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
KYTX
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Stocktwits
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
NeutralKYTXSeptember 24, 2026
StocktwitsNeutral
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
KYTX

24/7 Wall Street
Kyverna Therapeutics Sinks 13%: Here's Why
NeutralKYTXJuly 10, 2026
24/7 Wall StreetNeutral
Kyverna Therapeutics Sinks 13%: Here's Why
KYTX

The Motley Fool
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
NeutralKYTXJune 8, 2026
The Motley FoolNeutral
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
KYTX

Stocktwits
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
NeutralKYTXApril 22, 2026
StocktwitsNeutral
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
KYTX

Stocktwits
KYTX Stock Soars After Hours: What’s Driving The Rally?
NeutralKYTXApril 22, 2026
StocktwitsNeutral
KYTX Stock Soars After Hours: What’s Driving The Rally?
KYTX

24/7 Wall Street
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
NeutralKYTXFebruary 16, 2026
24/7 Wall StreetNeutral
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
KYTX

Zacks Investment Research
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
NeutralKYTXDecember 30, 2025
Zacks Investment ResearchNeutral
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX

Zacks Investment Research
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
NeutralKYTXDecember 16, 2025
Zacks Investment ResearchNeutral
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
KYTX

Zacks Investment Research
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
NeutralKYTXDecember 16, 2025
Zacks Investment ResearchNeutral
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
KYTX

Stocktwits
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?
NeutralKYTXDecember 15, 2025
StocktwitsNeutral
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?
KYTX
About Kyverna Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees149
CEOMr. Warner Biddle
IPO DateFeb 8, 2024
HeadquartersEmeryVille, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Christi L. Shaw | Executive Chairperson | 1967 |
| Mr. Warner Biddle | CEO & Director | 1967 |
| Dr. Naji H. Gehchan M.B.A., M.D. | Chief Medical & Development Officer | 1982 |
| Mr. Gregory Martini | Chief Financial Officer | 1989 |
| Dr. Tom Van Blarcom Ph.D. | Senior VP & Head of Research | — |
| Mr. Mayo Pujols | Chief Technology Officer | 1970 |
| Ms. Jessica Serra | Head of Investor Relations | — |
| Mr. Ritesh Srivastava | Chief Legal & Compliance Officer | — |
| Ms. Cara Bauer Ph.D. | Chief Human Resources Officer | — |
| Ms. Tracy Rossin | Senior Vice President of Corporate Affairs | 1977 |
Fundamentals
Valuation
Market cap$421.15M
Price-to-sales ratioN/A
Price-to-book value2.61
Price-earnings ratio-2.80
Return on Equity-82.00%
Return on SalesN/A
Return on Assets-65.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.93
Income Statement
Average volume855,944
EBITDA$-150.80M
1 year high (52w)$13.67
1 year low (52w)$5.30
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -9.4 | -10.5 | -32.8 | -24.6 | -42.6 | +10.9 | +2.3 | -33.6 | +1.1 | +18.0 | -42.4 | |
| 2025 | -17.3 | -8.4 | -25.5 | +16.7 | +14.9 | +15.8 | +28.9 | +7.8 | +67.1 | +16.8 | +11.5 | +39.7 |
| 2026 | -8.7 | -1.4 | +1.4 | +0.3 | -3.9 | +8.4 | -13.5 | +12.9 | -18.4 |



